NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease

Countries: Switzerland

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Eligibility overview

Sex: ALL

Age: 1 Year to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

Exclusion criteria:

• Patients Aged \<2 Years (24 Months) at Index Date.

Locations (1)

Basel, Switzerland